CCR4 and tropical spastic paraparesis: Administration of Mogamulizumab/KW-0761, as a humanized anti-CCR4 monoclonal antibody (mAb), in HAM/TSP, has reduced the number of HTLV-1 infected cells and inflammatory markers.